The guidance withdrawal and strategic alternatives review signal heightened uncertainty around Heron's standalone viability, particularly for CINVANTI. Traders should monitor for any sale/restructuring announcements and the outcome of the CINVANTI patent appeal. The credit facility amendment provides near-term liquidity relief but does not address the core revenue risk.
Price Chart
Executive Summary
Heron Therapeutics withdrew full-year 2026 guidance and announced a strategic alternatives review, citing a June 2026 court decision on CINVANTI patents that introduces uncertainty around generic entry for its largest product. Q2 2026 revenue of $37.7M (+1.3% YoY) missed the implied quarterly run rate of prior guidance, and GAAP EPS of -$0.03 missed consensus of -$0.02. The company also amended its Hercules Capital credit facility to reduce principal by $13.5M immediately with a potential further $4M reduction, and paused its planned sales force expansion.
Key Financial Metrics
Key Facts
- Q2 2026 net revenue $37.7M, up 1.3% YoY from $37.2M
- GAAP EPS -$0.03 vs consensus -$0.02 (50% miss)
- Withdrew full-year 2026 guidance for net revenue and Adjusted EBITDA
- CINVANTI patent litigation: June 2026 court decision creates uncertainty about generic entry timing/terms
- Amended credit facility with Hercules Capital: $13.5M principal reduction at execution, potential $4M further reduction by Sept 15, 2026
- Considering strategic alternatives; no timetable set
- Paused sales force expansion and tightened spending
- Cash, cash equivalents and short-term investments: $42.7M at June 30, 2026
- Acute Care franchise grew 43.9% YoY; Oncology franchise declined 15.9% YoY
- Net loss $5.5M in Q2 2026 vs $2.4M loss in Q2 2025
Financial Impact
Guidance withdrawal and strategic review imply material downside risk; revenue run rate (~$150M annualized) well below prior guidance of $173-183M
Risk Factors
- Generic entry for CINVANTI could significantly erode the largest revenue contributor
- Strategic alternatives process may not result in a transaction, leading to further downside
- Cash burn continues with net losses; $42.7M cash may not sustain operations beyond 12-18 months without a deal
- Potential Nasdaq delisting if stock price remains low
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-341300 |
| Document: hrtx-20260810.htm | 0001193125-26-341300 |
| Document: 0001193125-26-341300-index-headers.html | 0001193125-26-341300 |
| Document: 0001193125-26-341300-index.html | 0001193125-26-341300 |
| Document: 0001193125-26-341300.txt | 0001193125-26-341300 |
| 8-K Data (Synthetic) | 0001193125-26-341300 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 11w ago | 8-K | $0.3350 | awaiting T+60 | — | $0.3000 (+10.45%) |
Aug 10, 2026 11w ago | Press Release | $0.3350 | awaiting T+60 | — | $0.3000 (+10.45%) |
Jun 25, 2026 17w ago | 8-K | $0.4300 $0.2700 | ▲ +37.21% | ▲ +43.31% | $0.3000 (+30.23%) |
Jun 2, 2026 20w ago | 8-K | $0.4500 $0.3321 | ▲ +26.20% | ▲ +28.70% | $0.3000 (+33.33%) |
May 11, 2026 24w ago | 8-K | $0.9600 $0.5048 | ▲ +47.42% | ▲ +51.81% | $0.3000 (+68.75%) |
May 11, 2026 24w ago | Press Release | $0.9600 $0.5048 | ▲ +47.42% | ▲ +51.81% | $0.3000 (+68.75%) |
Apr 30, 2026 25w ago | DEFA14A | $1.20 $0.4592 | ▼ −61.73% | ▼ −64.84% | $0.3000 (−75.00%) |
Apr 27, 2026 26w ago | Press Release | $1.21 $0.4590 | ▼ −62.07% | ▼ −66.06% | $0.3000 (−75.21%) |
Apr 6, 2026 29w ago | 8-K | $0.8100 $0.4244 | ▼ −47.60% | ▼ −61.07% | $0.3000 (−62.96%) |
Feb 26, 2026 34w ago | 8-K | $1.20 $0.8700 | ▼ −27.50% | ▼ −35.25% | $0.3000 (−75.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers